SCHEMBL7125938

SCHEMBL7125938

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)NCCO

nearest known ligand 0.77

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ACHE P22303 14/20 0.77
EPHX1 P07099 2/20 0.61
EPHX2 P34913 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8810707 1.00 ACHE (0.77) ACHEEPHX1EPHX2
SCHEMBL9740500 1.00 ACHE (0.77) ACHEEPHX1EPHX2
Hydrochloric Acid SCHEMBL5331492 0.98 ACHE (0.75) ACHEEPHX1EPHX2
SCHEMBL18683485 0.93 ACHE (0.69) ACHEEPHX1EPHX2
SCHEMBL605034 0.92 ACHE (0.72) ACHEEPHX1
SCHEMBL10062061 0.90 ACHE (0.67) ACHEEPHX1EPHX2
SCHEMBL27051136 0.89 ACHE (0.90) ACHEEPHX1EPHX2
SCHEMBL27051138 0.89 ACHE (0.90) ACHEEPHX1EPHX2
SCHEMBL14891267 0.89 ACHE (0.90) ACHEEPHX1EPHX2
SCHEMBL7693663 0.89 ACHE (0.89) ACHEEPHX1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030097011-A1 Novel carbamate-based cationic lipids PROMEGA BIOSCIENCES, INC. (US) 2003-05-22 US claimed
EP-0830368-A1 NOVEL CARBAMATE-BASED CATIONIC LIPIDS GENTA INCORPORATED (US) 1998-03-25 EP claimed
WO-1996040726-A9 NOVEL CARBAMATE-BASED CATIONIC LIPIDS 1997-02-06 WO claimed
WO-1996040726-A1 NOVEL CARBAMATE-BASED CATIONIC LIPIDS GENTA INCORPORATED (US) 1996-12-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030097011-A1 Novel carbamate-based cationic lipids SGMS1, CETP, PCYT1A ACHE 3039/4885EPHX1 3887/4885EPHX2 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.